# GSK catalysts: GSK plc PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/gsk/catalysts

> GSK plc (GSK) has 154 upcoming catalysts. The next is the Jemperli (dostarlimab) primary completion, November 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, year only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | GSK plc |
| Ticker | GSK (NYSE) |
| SEC CIK | 1131399 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/gsk |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 4, 2016 | [Selzentry (maraviroc) FDA approval](https://sec-api.dev/pdufa/maraviroc) | GSK |  | completed, approved | "NDA208984 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20161104, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product SELZENTRY (MARAVIROC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208984%22)) |
| March 27, 2017 | [ZEJULA (niraparib) FDA approval](https://sec-api.dev/pdufa/niraparib) | GSK |  | completed, approved | "NDA208447 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20170327, review_priority PRIORITY; sponsor_name GLAXOSMITHKLINE; product ZEJULA (NIRAPARIB TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208447%22)) |
| July 20, 2017 | [Benlysta (belimumab) FDA approval](https://sec-api.dev/pdufa/belimumab) | GSK |  | completed, approved | "BLA761043 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20170720, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE LLC; product BENLYSTA (BELIMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761043%22)) |
| September 18, 2017 | [Trelegy Ellipta (fluticasone furoate; umeclidinium bromide; vilanterol trifenatate) FDA approval](https://sec-api.dev/pdufa/fluticasone-furoate-umeclidinium-vilanterol-trifenatate) | GSK |  | completed, approved | "NDA209482 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20170918, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE; product TRELEGY ELLIPTA (FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209482%22)) |
| November 21, 2017 | [Juluca (dolutegravir sodium; rilpivirine hydrochloride) FDA approval](https://sec-api.dev/pdufa/dolutegravir-rilpivirine) | GSK |  | completed, approved | "NDA210192 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20171121, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product JULUCA (DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210192%22)) |
| July 20, 2018 | [ARAKODA® (tafenoquine) FDA approval](https://sec-api.dev/pdufa/tafenoquine) | GSK |  | completed, approved | "NDA210795 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20180720, review_priority PRIORITY; sponsor_name GLAXOSMITHKLINE; product KRINTAFEL (TAFENOQUINE SUCCINATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210795%22)) |
| April 8, 2019 | [Dovato (dolutegravir sodium; lamivudine) FDA approval](https://sec-api.dev/pdufa/dolutegravir-lamivudine) | GSK |  | completed, approved | "NDA211994 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20190408, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product DOVATO (DOLUTEGRAVIR SODIUM; LAMIVUDINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211994%22)) |
| June 6, 2019 | [Nucala (mepolizumab) FDA approval](https://sec-api.dev/pdufa/mepolizumab) | GSK |  | completed, approved | "BLA761122 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20190606, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE; product NUCALA (MEPOLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761122%22)) |
| December 19, 2019 | [Vocabria (cabotegravir sodium) complete response letter (CRL)](https://sec-api.dev/pdufa/cabotegravir) | GSK |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22212887Orig1s000%2C212888Orig1s000OtherActionLtrs.pdf%22)) |
| December 19, 2019 | [Cabenuva Kit (cabotegravir; rilpivirine) complete response letter (CRL)](https://sec-api.dev/pdufa/cabotegravir-rilpivirine) | GSK |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22212887Orig1s000%2C212888Orig1s000OtherActionLtrs.pdf%22)) |
| April 29, 2020 | [ZEJULA (niraparib) label expansion decision](https://sec-api.dev/pdufa/niraparib) | GSK |  | completed, approved | "NDA208447 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20200429, review_priority PRIORITY; sponsor_name GLAXOSMITHKLINE; product ZEJULA (NIRAPARIB TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208447%22)) |
| June 12, 2020 | [Tivicay (dolutegravir sodium) FDA approval](https://sec-api.dev/pdufa/dolutegravir) | GSK |  | completed, approved | "NDA213983 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20200612, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product TIVICAY PD (DOLUTEGRAVIR SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213983%22)) |
| June 12, 2020 | [Tivicay (dolutegravir sodium) label expansion decision](https://sec-api.dev/pdufa/dolutegravir) | GSK |  | completed, approved | "NDA204790 SUPPL-25 (Efficacy): submission_status AP, submission_status_date 20200612, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product TIVICAY (DOLUTEGRAVIR SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204790%22)) |
| July 2, 2020 | [Rukobia (fostemsavir tromethamine) FDA approval](https://sec-api.dev/pdufa/fostemsavir) | GSK |  | completed, approved | "NDA212950 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20200702, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product RUKOBIA (FOSTEMSAVIR TROMETHAMINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212950%22)) |
| July 14, 2020 | [Juluca (dolutegravir sodium; rilpivirine hydrochloride) label expansion decision](https://sec-api.dev/pdufa/dolutegravir-rilpivirine) | GSK |  | completed, approved | "NDA210192 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20200714, review_priority STANDARD; sponsor_name VIIV HLTHCARE; product JULUCA (DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210192%22)) |
| August 6, 2020 | [Dovato (dolutegravir sodium; lamivudine) label expansion decision](https://sec-api.dev/pdufa/dolutegravir-lamivudine) | GSK |  | completed, approved | "NDA211994 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20200806, review_priority STANDARD; sponsor_name VIIV HLTHCARE; product DOVATO (DOLUTEGRAVIR SODIUM; LAMIVUDINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211994%22)) |
| September 9, 2020 | [Trelegy Ellipta (fluticasone furoate; umeclidinium bromide; vilanterol trifenatate) label expansion decision](https://sec-api.dev/pdufa/fluticasone-furoate-umeclidinium-vilanterol-trifenatate) | GSK |  | completed, approved | "NDA209482 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20200909, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE; product TRELEGY ELLIPTA (FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209482%22)) |
| September 25, 2020 | [Nucala (mepolizumab) label expansion decision](https://sec-api.dev/pdufa/mepolizumab) | GSK |  | completed, approved | "BLA125526 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20200925, review_priority PRIORITY; sponsor_name GLAXOSMITHKLINE LLC; product NUCALA (MEPOLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125526%22)) |
| October 30, 2020 | [Selzentry (maraviroc) label expansion decision](https://sec-api.dev/pdufa/maraviroc) | GSK |  | completed, approved | "NDA208984 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20201030, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product SELZENTRY (MARAVIROC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208984%22)) |
| December 16, 2020 | [Benlysta (belimumab) label expansion decision](https://sec-api.dev/pdufa/belimumab) | GSK |  | completed, approved | "BLA761043 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20201216, review_priority PRIORITY; sponsor_name GLAXOSMITHKLINE LLC; product BENLYSTA (BELIMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761043%22)) |
| January 21, 2021 | [Vocabria (cabotegravir sodium) FDA approval](https://sec-api.dev/pdufa/cabotegravir) | GSK |  | completed, approved | "NDA212887 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20210121, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product VOCABRIA (CABOTEGRAVIR SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212887%22)) |
| January 21, 2021 | [Cabenuva Kit (cabotegravir; rilpivirine) FDA approval](https://sec-api.dev/pdufa/cabotegravir-rilpivirine) | GSK |  | completed, approved | "NDA212888 ORIG-1 (Type 1 - New Molecular Entity and Type 4 - New Combination): submission_status AP, submission_status_date 20210121, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product CABENUVA KIT (CABOTEGRAVIR; RILPIVIRINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212888%22)) |
| March 1, 2021 | [Triumeq Pd (abacavir sulfate; dolutegravir sodium; lamivudine) label expansion decision](https://sec-api.dev/pdufa/abacavir-dolutegravir-lamivudine) | GSK |  | completed, approved | "NDA205551 SUPPL-25 (Efficacy): submission_status AP, submission_status_date 20210301, review_priority STANDARD; sponsor_name VIIV HLTHCARE; product TRIUMEQ (ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205551%22)) |
| March 1, 2021 | [Dovato (dolutegravir sodium; lamivudine) label expansion decision](https://sec-api.dev/pdufa/dolutegravir-lamivudine) | GSK |  | completed, approved | "NDA211994 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20210301, review_priority STANDARD; sponsor_name VIIV HLTHCARE; product DOVATO (DOLUTEGRAVIR SODIUM; LAMIVUDINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211994%22)) |
| April 22, 2021 | [Jemperli (dostarlimab-gxly) FDA approval](https://sec-api.dev/pdufa/dostarlimab-gxly) | GSK |  | completed, approved | "BLA761174 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20210422, review_priority PRIORITY; sponsor_name GLAXOSMITHKLINE; product JEMPERLI (DOSTARLIMAB-GXLY)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761174%22)) |
| June 1, 2021 | [Brexafemme (ibrexafungerp) FDA approval](https://sec-api.dev/pdufa/ibrexafungerp) | GSK |  | completed, approved | "NDA214900 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20210601, review_priority PRIORITY; sponsor_name GLAXOSMITHKLINE; product BREXAFEMME (IBREXAFUNGERP CITRATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214900%22)) |
| July 9, 2021 | [Tivicay (dolutegravir sodium) label expansion decision](https://sec-api.dev/pdufa/dolutegravir) | GSK |  | completed, approved | "NDA204790 SUPPL-28 (Efficacy): submission_status AP, submission_status_date 20210709, review_priority STANDARD; sponsor_name VIIV HLTHCARE; product TIVICAY (DOLUTEGRAVIR SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204790%22)) |
| July 9, 2021 | [Juluca (dolutegravir sodium; rilpivirine hydrochloride) label expansion decision](https://sec-api.dev/pdufa/dolutegravir-rilpivirine) | GSK |  | completed, approved | "NDA210192 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20210709, review_priority STANDARD; sponsor_name VIIV HLTHCARE; product JULUCA (DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210192%22)) |
| July 29, 2021 | [Nucala (mepolizumab) label expansion decision](https://sec-api.dev/pdufa/mepolizumab) | GSK |  | completed, approved | "BLA125526 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20210729, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE LLC; product NUCALA (MEPOLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125526%22)) |
| August 17, 2021 | [Jemperli (dostarlimab-gxly) FDA approval](https://sec-api.dev/pdufa/dostarlimab-gxly) | GSK |  | completed, approved | "BLA761223 ORIG-1 (Type 9 - New indication submitted as distinct BLA, consolidated): submission_status AP, submission_status_date 20210817, review_priority PRIORITY; sponsor_name GLAXOSMITHKLINE LLC; product JEMPERLI (DOSTARLIMAB-GXLY)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761223%22)) |
| December 10, 2021 | [Epzicom (abacavir sulfate; lamivudine) label expansion decision](https://sec-api.dev/pdufa/abacavir-lamivudine) | GSK |  | completed, approved | "NDA021652 SUPPL-29 (Efficacy): submission_status AP, submission_status_date 20211210, review_priority STANDARD; sponsor_name VIIV HLTHCARE; product EPZICOM (ABACAVIR SULFATE; LAMIVUDINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA021652%22)) |
| December 20, 2021 | [Vocabria (cabotegravir sodium) FDA approval](https://sec-api.dev/pdufa/cabotegravir) | GSK |  | completed, approved | "NDA215499 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20211220, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product APRETUDE (CABOTEGRAVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215499%22)) |
| December 20, 2021 | [Vocabria (cabotegravir sodium) label expansion decision](https://sec-api.dev/pdufa/cabotegravir) | GSK |  | completed, approved | "NDA212887 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20211220, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product VOCABRIA (CABOTEGRAVIR SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212887%22)) |
| January 20, 2022 | [Dovato (dolutegravir sodium; lamivudine) label expansion decision](https://sec-api.dev/pdufa/dolutegravir-lamivudine) | GSK |  | completed, approved | "NDA211994 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20220120, review_priority STANDARD; sponsor_name VIIV HLTHCARE; product DOVATO (DOLUTEGRAVIR SODIUM; LAMIVUDINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211994%22)) |
| January 24, 2022 | [Rukobia (fostemsavir tromethamine) label expansion decision](https://sec-api.dev/pdufa/fostemsavir) | GSK |  | completed, approved | "NDA212950 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20220124, review_priority STANDARD; sponsor_name VIIV HLTHCARE; product RUKOBIA (FOSTEMSAVIR TROMETHAMINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212950%22)) |
| January 31, 2022 | [Vocabria (cabotegravir sodium) label expansion decision](https://sec-api.dev/pdufa/cabotegravir) | GSK |  | completed, approved | "NDA212887 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20220131, review_priority STANDARD; sponsor_name VIIV HLTHCARE; product VOCABRIA (CABOTEGRAVIR SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212887%22)) |
| January 31, 2022 | [Cabenuva Kit (cabotegravir; rilpivirine) label expansion decision](https://sec-api.dev/pdufa/cabotegravir-rilpivirine) | GSK |  | completed, approved | "NDA212888 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20220131, review_priority STANDARD; sponsor_name VIIV HLTHCARE; product CABENUVA KIT (CABOTEGRAVIR; RILPIVIRINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212888%22)) |
| March 23, 2022 | [Vocabria (cabotegravir sodium) label expansion decision](https://sec-api.dev/pdufa/cabotegravir) | GSK |  | completed, approved | "NDA212887 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20220323, review_priority STANDARD; sponsor_name VIIV HLTHCARE; product VOCABRIA (CABOTEGRAVIR SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212887%22)) |
| March 23, 2022 | [Cabenuva Kit (cabotegravir; rilpivirine) label expansion decision](https://sec-api.dev/pdufa/cabotegravir-rilpivirine) | GSK |  | completed, approved | "NDA212888 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20220323, review_priority STANDARD; sponsor_name VIIV HLTHCARE; product CABENUVA KIT (CABOTEGRAVIR; RILPIVIRINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212888%22)) |
| March 30, 2022 | [Triumeq Pd (abacavir sulfate; dolutegravir sodium; lamivudine) FDA approval](https://sec-api.dev/pdufa/abacavir-dolutegravir-lamivudine) | GSK |  | completed, approved | "NDA215413 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20220330, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product TRIUMEQ PD (ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215413%22)) |
| March 30, 2022 | [Triumeq Pd (abacavir sulfate; dolutegravir sodium; lamivudine) label expansion decision](https://sec-api.dev/pdufa/abacavir-dolutegravir-lamivudine) | GSK |  | completed, approved | "NDA205551 SUPPL-28 (Efficacy): submission_status AP, submission_status_date 20220330, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product TRIUMEQ (ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205551%22)) |
| November 30, 2022 | [Brexafemme (ibrexafungerp) label expansion decision](https://sec-api.dev/pdufa/ibrexafungerp) | GSK |  | completed, approved | "NDA214900 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20221130, review_priority PRIORITY; sponsor_name GLAXOSMITHKLINE; product BREXAFEMME (IBREXAFUNGERP CITRATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214900%22)) |
| December 8, 2022 | [ZEJULA (niraparib) label expansion decision](https://sec-api.dev/pdufa/niraparib) | GSK |  | completed, approved | "NDA208447 SUPPL-25 (Efficacy): submission_status AP, submission_status_date 20221208, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE; product ZEJULA (NIRAPARIB TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208447%22)) |
| January 25, 2023 | [Dovato (dolutegravir sodium; lamivudine) label expansion decision](https://sec-api.dev/pdufa/dolutegravir-lamivudine) | GSK |  | completed, approved | "NDA211994 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20230125, review_priority STANDARD; sponsor_name VIIV HLTHCARE; product DOVATO (DOLUTEGRAVIR SODIUM; LAMIVUDINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211994%22)) |
| February 1, 2023 | [Jesduvroq (daprodustat) FDA approval](https://sec-api.dev/pdufa/daprodustat) | GSK |  | completed, approved | "Jesduvroq \| daprodustat \| 2/1/2023 \| To treat anemia caused by chronic kidney disease for adults on dialysis for at least four monthsPress ReleaseDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)) |
| February 9, 2023 | [Jemperli (dostarlimab-gxly) label expansion decision](https://sec-api.dev/pdufa/dostarlimab-gxly) | GSK |  | completed, approved | "BLA761174 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20230209, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE; product JEMPERLI (DOSTARLIMAB-GXLY)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761174%22)) |
| February 15, 2023 | [Benlysta (belimumab) label expansion decision](https://sec-api.dev/pdufa/belimumab) | GSK |  | completed, approved | "BLA761043 SUPPL-22 (Efficacy): submission_status AP, submission_status_date 20230215, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE LLC; product BENLYSTA (BELIMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761043%22)) |
| March 1, 2023 | [Arnuity Ellipta (fluticasone furoate) label expansion decision](https://sec-api.dev/pdufa/fluticasone-furoate) | GSK |  | completed, approved | "NDA205625 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20230301, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE; product ARNUITY ELLIPTA (FLUTICASONE FUROATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205625%22)) |
| April 26, 2023 | [ZEJULA (niraparib) FDA approval](https://sec-api.dev/pdufa/niraparib) | GSK |  | completed, approved | "NDA214876 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20230426, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE; product ZEJULA (NIRAPARIB TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214876%22)) |
| April 26, 2023 | [ZEJULA (niraparib) label expansion decision](https://sec-api.dev/pdufa/niraparib) | GSK |  | completed, approved | "NDA208447 SUPPL-27 (Efficacy): submission_status AP, submission_status_date 20230426, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE; product ZEJULA (NIRAPARIB TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208447%22)) |
| June 15, 2023 | [Triumeq Pd (abacavir sulfate; dolutegravir sodium; lamivudine) label expansion decision](https://sec-api.dev/pdufa/abacavir-dolutegravir-lamivudine) | GSK |  | completed, approved | "NDA215413 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20230615, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product TRIUMEQ PD (ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215413%22)) |
| July 31, 2023 | [Jemperli (dostarlimab-gxly) label expansion decision](https://sec-api.dev/pdufa/dostarlimab-gxly) | GSK |  | completed, approved | "BLA761174 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20230731, review_priority PRIORITY; sponsor_name GLAXOSMITHKLINE; product JEMPERLI (DOSTARLIMAB-GXLY)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761174%22)) |
| Sep 2023 | [GSK plc PDUFA date](https://sec-api.dev/companies/gsk/catalysts) | GSK |  | scheduled | "Last rating action date: September 2023" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495425001166/finalresults05-0225.htm)) |
| September 15, 2023 | [OJJAARA (momelotinib) FDA approval](https://sec-api.dev/pdufa/momelotinib) | GSK | To treat intermediate or high-risk myelofibrosis in adults with anemia | completed, approved | "Ojjaara \| momelotinib \| 9/15/2023 \| To treat intermediate or high-risk myelofibrosis in adults with anemiaDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)) |
| April 5, 2024 | [Dovato (dolutegravir sodium; lamivudine) label expansion decision](https://sec-api.dev/pdufa/dolutegravir-lamivudine) | GSK |  | completed, approved | "NDA211994 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20240405, review_priority STANDARD; sponsor_name VIIV HLTHCARE; product DOVATO (DOLUTEGRAVIR SODIUM; LAMIVUDINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211994%22)) |
| May 16, 2024 | [Benlysta (belimumab) label expansion decision](https://sec-api.dev/pdufa/belimumab) | GSK |  | completed, approved | "BLA761043 SUPPL-27 (Efficacy): submission_status AP, submission_status_date 20240516, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE LLC; product BENLYSTA (BELIMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761043%22)) |
| August 1, 2024 | [Jemperli (dostarlimab-gxly) label expansion decision](https://sec-api.dev/pdufa/dostarlimab-gxly) | GSK |  | completed, approved | "BLA761174 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20240801, review_priority PRIORITY; sponsor_name GLAXOSMITHKLINE; product JEMPERLI (DOSTARLIMAB-GXLY)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761174%22)) |
| September 20, 2024 | [Vocabria (cabotegravir sodium) label expansion decision](https://sec-api.dev/pdufa/cabotegravir) | GSK |  | completed, approved | "NDA212887 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20240920, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product VOCABRIA (CABOTEGRAVIR SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212887%22)) |
| September 20, 2024 | [Cabenuva Kit (cabotegravir; rilpivirine) label expansion decision](https://sec-api.dev/pdufa/cabotegravir-rilpivirine) | GSK |  | completed, approved | "NDA212888 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20240920, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product CABENUVA KIT (CABOTEGRAVIR; RILPIVIRINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212888%22)) |
| February 14, 2025 | [GSK plc PDUFA date](https://sec-api.dev/companies/gsk/catalysts) | GSK |  | scheduled | "action date of 14 February 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495425001166/finalresults05-0225.htm)) |
| February 14, 2025 | [GSK plc FDA approval](https://sec-api.dev/companies/gsk/catalysts) | GSK |  | completed, approved | "On 14 February 2025, the US Food and Drug Administration (FDA) approved GSK's" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495425004375/a3700f.htm)) |
| Mar 2025 | [GSK plc FDA approval](https://sec-api.dev/companies/gsk/catalysts) | GSK | female adults | completed, approved | "March 2025, the US FDA approved Blujepa (gepotidacin) for the treatment of female adults (≥40 kg) and paediatric patients (≥12 years, ≥40 kg) with uncomplicated urinary tract infections (uUTIs) caused by the following susceptible microorganisms:" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495425004827/a7053g-59446108resubmissi.htm)) |
| March 25, 2025 | [Blujepa (gepotidacin mesylate) FDA approval](https://sec-api.dev/pdufa/gepotidacin) | GSK | To treat uncomplicated urinary tract infections | completed, approved | "Blujepa \| gepotidacin \| 3/25/2025 \| To treat uncomplicated urinary tract infectionsDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| May 19, 2025 | [Gsk3511294 (depemokimab) primary completion](https://sec-api.dev/pdufa/gsk3511294-depemokimab) | GSK | Asthma | completed | "NCT05243680 (An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-19 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-01-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05243680)) |
| May 22, 2025 | [Nucala (mepolizumab) label expansion decision](https://sec-api.dev/pdufa/mepolizumab) | GSK |  | completed, approved | "BLA125526 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20250522, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE LLC; product NUCALA (MEPOLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125526%22)) |
| May 27, 2025 | [GSK3036656 primary completion](https://sec-api.dev/pdufa/gsk3036656) | GSK | Tuberculosis | completed | "NCT05382312 (Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-27 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-06-17." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05382312)) |
| June 3, 2025 | [Rsvpref3 oa investigational vaccine primary completion](https://sec-api.dev/pdufa/rsvpref3-oa-investigational-vaccine) | GSK | Respiratory Syncytial Virus Infections | completed | "NCT06614725 (A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-03 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-06-23." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06614725)) |
| June 5, 2025 | [Cobolimab primary completion](https://sec-api.dev/pdufa/cobolimab) | GSK | Lung Cancer, Non-Small Cell | completed | "NCT04655976 (Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-06-05 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-07-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04655976)) |
| June 18, 2025 | [ZEJULA (niraparib) label expansion decision](https://sec-api.dev/pdufa/niraparib) | GSK |  | completed, approved | "NDA214876 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20250618, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE; product ZEJULA (NIRAPARIB TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214876%22)) |
| June 20, 2025 | [Benlysta (belimumab) label expansion decision](https://sec-api.dev/pdufa/belimumab) | GSK |  | completed, approved | "BLA761043 SUPPL-34 (Efficacy): submission_status AP, submission_status_date 20250620, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE LLC; product BENLYSTA (BELIMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761043%22)) |
| July 17, 2025 | [Blenrep (belantamab mafodotin-blmf) FDA advisory committee meeting](https://sec-api.dev/pdufa/belantamab-mafodotin-blmf) | GSK |  | completed, negative | "The Committee will discuss BLA 761440, belantamab mafodotin submitted by GlaxoSmithKline LLC, for the treatment of adults with multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior line of therapy; and in combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide." ([FDA advisory committee calendar](https://www.fda.gov/advisory-committees/july-17-2025-meeting-oncologic-drugs-advisory-committee-07172025)) |
| July 23, 2025 | [GSK plc PDUFA date](https://sec-api.dev/companies/gsk/catalysts) | GSK |  | scheduled | "The US FDA has assigned a Prescription Drug User Fee Act action date of 23 July 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495425001166/finalresults05-0225.htm)) |
| July 23, 2025 | [GSK1070806 primary completion](https://sec-api.dev/pdufa/gsk1070806) | GSK | Dermatitis, Atopic | withdrawn | "NCT05999799 (A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-07-23 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-06-03." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05999799)) |
| July 29, 2025 | [GSK1070806 primary completion](https://sec-api.dev/pdufa/gsk1070806) | GSK | Dermatitis, Atopic | withdrawn | "NCT06447506 (Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-07-29 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-06-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06447506)) |
| July 30, 2025 | [GSK plc FDA advisory committee meeting](https://sec-api.dev/companies/gsk/catalysts) | GSK |  | completed | "This follows the US FDA Oncologic Drugs Advisory Committee (ODAC) vote against the overall benefit/risk profile at the proposed dosage of" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495425008641/a0713t-gskplc2ndquarterre.htm)) |
| August 5, 2025 | [HIBSAGO (bepirovirsen) primary completion](https://sec-api.dev/pdufa/bepirovirsen) | GSK | Hepatitis B, Chronic | completed | "NCT05276297 (A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-08-05 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05276297)) |
| September 2, 2025 | [Salbutamol hfa-134a primary completion](https://sec-api.dev/pdufa/salbutamol-hfa-134a) | GSK | Asthma | completed | "NCT06261957 (A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-02 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-10-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06261957)) |
| September 14, 2025 | [Nucala (mepolizumab) primary completion](https://sec-api.dev/pdufa/mepolizumab) | GSK | Asthma | completed | "NCT04718389 (A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-14 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-05-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04718389)) |
| September 16, 2025 | [Dtg/3tc primary completion](https://sec-api.dev/pdufa/dtg-3tc) | GSK | HIV Infections | completed | "NCT05917509 (A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-16 (ACTUAL); Lead Sponsor ViiV Healthcare." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05917509)) |
| September 18, 2025 | [AFX3772 primary completion](https://sec-api.dev/pdufa/afx3772) | GSK | Pneumonia, Bacterial; Pneumococcal Infections; Pneumonia, Pneumococcal | completed | "NCT05412030 (A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-18 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-10-09." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05412030)) |
| September 23, 2025 | [GSK4532990 primary completion](https://sec-api.dev/pdufa/gsk4532990) | GSK | Non-alcoholic Fatty Liver Disease | completed | "NCT06104319 (Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-23 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-10-27." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06104319)) |
| October 1, 2025 | [GSK3915393 primary completion](https://sec-api.dev/pdufa/gsk3915393) | GSK | Idiopathic Pulmonary Fibrosis | withdrawn | "NCT06317285 (A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-10-01 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-09-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06317285)) |
| October 21, 2025 | [Altsonflex1-2-3 dose a primary completion](https://sec-api.dev/pdufa/altsonflex1-2-3) | GSK | Diarrhoea | completed | "NCT06663436 (A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-21 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-10-26." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06663436)) |
| October 23, 2025 | [GSK plc PDUFA date](https://sec-api.dev/companies/gsk/catalysts) | GSK |  | scheduled | "Constructive discussion ongoing with FDA with new PDUFA date set for 23 October 2025" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495425008641/a0713t-gskplc2ndquarterre.htm)) |
| October 23, 2025 | [Blenrep (belantamab mafodotin-blmf) FDA approval](https://sec-api.dev/pdufa/belantamab-mafodotin-blmf) | GSK |  | completed, approved | "BLA761440 ORIG-1 (Type 2 - New Active Ingredient): submission_status AP, submission_status_date 20251023, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE LLC; product BLENREP (BELANTAMAB MAFODOTIN-BLMF)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761440%22)) |
| October 23, 2025 | [Blenrep (belantamab mafodotin-blmf) complete response letter (CRL)](https://sec-api.dev/pdufa/belantamab-mafodotin-blmf) | GSK |  | completed, complete response letter | "We have completed the review of BLA 761440/Original 2, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761440_20251023.pdf%22)) |
| October 27, 2025 | [Efimosfermin primary completion](https://sec-api.dev/pdufa/efimosfermin) | GSK | Nonalcoholic Steatohepatitis (NASH) | completed | "NCT04880031 (A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-27 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04880031)) |
| October 28, 2025 | [Nucala (mepolizumab) primary completion](https://sec-api.dev/pdufa/mepolizumab) | GSK | Hypereosinophilic Syndrome | completed | "NCT04965636 (Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-28 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-05-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04965636)) |
| November 3, 2025 | [HIBSAGO (bepirovirsen) primary completion](https://sec-api.dev/pdufa/bepirovirsen) | GSK | Chronic Hepatitis B; Hepatitis B, Chronic | completed | "NCT05630820 (Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-03 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05630820)) |
| November 11, 2025 | [HIBSAGO (bepirovirsen) primary completion](https://sec-api.dev/pdufa/bepirovirsen) | GSK | Chronic Hepatitis B; Hepatitis B, Chronic | completed | "NCT05630807 (Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-11 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05630807)) |
| Dec 2025 | [GSK plc label expansion decision](https://sec-api.dev/companies/gsk/catalysts) | GSK | uncomplicated urogenital gonorrhoea in patients 12 years of age and older | completed, approved | "In December 2025, the US FDA approved a supplemental New Drug Application for gepotidacin as an oral option for the treatment of uncomplicated urogenital gonorrhoea in patients 12 years of age and older (weighing >45 kg) with limited or no alternative." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495426000892/a5979rv2.htm)) |
| Dec 2025 | [Azithromycin PDUFA date](https://sec-api.dev/pdufa/azithromycin) | GSK |  | scheduled | "Prescription Drug User Fee Act action date in December 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495425009314/a6948u.htm)) |
| December 11, 2025 | [GSK plc PDUFA date](https://sec-api.dev/companies/gsk/catalysts) | GSK |  | scheduled | "Act action date of 11 December 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495425012307/a1902f-gskoriginaledgar.htm)) |
| December 11, 2025 | [Blujepa (gepotidacin mesylate) label expansion decision](https://sec-api.dev/pdufa/gepotidacin) | GSK |  | completed, approved | "NDA218230 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20251211, review_priority PRIORITY; sponsor_name GLAXOSMITHKLINE; product BLUJEPA (GEPOTIDACIN MESYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218230%22)) |
| December 15, 2025 | [Rmenb+omv nz vaccine primary completion](https://sec-api.dev/pdufa/rmenb-omv-nz-vaccine) | GSK | Meningitis | completed | "NCT06995430 (A Phase 3 Study to Assess the Immune Response and Safety of rMenB+OMV NZ in Primed Healthy Participants (10 to 20 Years Old)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-15 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-11-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06995430)) |
| December 16, 2025 | [Exdensur (depemokimab-ulaa) FDA approval](https://sec-api.dev/pdufa/depemokimab-ulaa) | GSK |  | completed, approved | "Exdensur \| depemokimab-ulaa \| 12/16/2025 \| To treat severe asthma characterized by an eosinophilic phenotype as an Komziftiadd-on maintenance therapyDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| December 16, 2025 | [Exdensur (depemokimab-ulaa) complete response letter (CRL)](https://sec-api.dev/pdufa/depemokimab-ulaa) | GSK |  | completed, complete response letter | "We have completed the review of BLA 761458/Original 2 and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761458_20251216.pdf%22)) |
| 2026 | [Rezetecan trial start](https://sec-api.dev/pdufa/rezetecan) | GSK |  | scheduled | "Through our BEHOLD global development programme, we're advancing mocertatug rezetecan in areas of high unmet medical need, with plans to initiate registrational phase III trials in 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1131399/000113139926000004/gsk-20251231.htm)) |
| January 14, 2026 | [Zanamivir primary completion](https://sec-api.dev/pdufa/zanamivir) | GSK | Influenza, Human; Arthralgia | completed | "NCT04494412 (An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza Infection): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-14 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04494412)) |
| January 15, 2026 | [Gsk3511294 (depemokimab) topline data readout](https://sec-api.dev/pdufa/gsk3511294-depemokimab) | GSK | Asthma | completed | "NCT05243680 (An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-19 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-01-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05243680?tab=results)) |
| January 23, 2026 | [Dtg/3tc primary completion](https://sec-api.dev/pdufa/dtg-3tc) | GSK | HIV; HIV Infections | completed | "NCT05911360 (A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-23 (ACTUAL); Lead Sponsor ViiV Healthcare; Results First Posted 2026-05-14." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05911360)) |
| January 31, 2026 | [GSK4532990 primary completion](https://sec-api.dev/pdufa/gsk4532990) | GSK | Nonalcoholic Fatty Liver Disease; Non-alcoholic Fatty Liver Disease | completed | "NCT05583344 (Phase 2b Study of GSK4532990 in Adults With NASH): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-31 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05583344)) |
| Mar 2026 | [GSK plc PDUFA date](https://sec-api.dev/companies/gsk/catalysts) | GSK |  | scheduled | "Last rating action date: March 2026" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495426004051/a2755c.htm)) |
| March 9, 2026 | [Wellcovorin (leucovorin calcium) label expansion decision](https://sec-api.dev/pdufa/leucovorin) | GSK |  | completed, approved | "NDA018342 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20260309, review_priority PRIORITY; sponsor_name GLAXOSMITHKLINE; product WELLCOVORIN (LEUCOVORIN CALCIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA018342%22)) |
| March 24, 2026 | [Linerixibat PDUFA date](https://sec-api.dev/pdufa/linerixibat) | GSK |  | scheduled | "Under the terms of the agreement, GSK will receive an upfront payment of $300 million, plus $100 million upon US FDA approval (expected prior to transaction closing, based on current PDUFA target approval date of 24 March 2026)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495426002008/a8361v.htm)) |
| April 15, 2026 | [Tivicay (dolutegravir sodium) primary completion](https://sec-api.dev/pdufa/dolutegravir) | GSK | HIV; HIV Infections | completed | "NCT05979311 (A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-15 (ACTUAL); Lead Sponsor ViiV Healthcare." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05979311)) |
| May 4, 2026 | [Nucala (mepolizumab) topline data readout](https://sec-api.dev/pdufa/mepolizumab) | GSK | Hypereosinophilic Syndrome | completed | "NCT04965636 (Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-28 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-05-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04965636?tab=results)) |
| May 11, 2026 | [Flu mrna (formulation a) primary completion](https://sec-api.dev/pdufa/flu-mrna-formulation-a) | GSK | Influenza, Human | completed | "NCT07121192 (A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-11 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07121192)) |
| May 14, 2026 | [Dtg/3tc topline data readout](https://sec-api.dev/pdufa/dtg-3tc) | GSK | HIV; HIV Infections | completed | "NCT05911360 (A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-23 (ACTUAL); Lead Sponsor ViiV Healthcare; Results First Posted 2026-05-14." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05911360?tab=results)) |
| May 14, 2026 | [GSK4527226 primary completion](https://sec-api.dev/pdufa/gsk4527226) | GSK | Alzheimer's Disease | withdrawn | "NCT06079190 (Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-05-14 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06079190)) |
| May 18, 2026 | [Nucala (mepolizumab) topline data readout](https://sec-api.dev/pdufa/mepolizumab) | GSK | Asthma | completed | "NCT04718389 (A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-14 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-05-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04718389?tab=results)) |
| May 27, 2026 | [Vocabria (cabotegravir sodium) primary completion](https://sec-api.dev/pdufa/cabotegravir) | GSK | HIV Infections | completed | "NCT05996471 (A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-05-27 (ACTUAL); Lead Sponsor ViiV Healthcare." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05996471)) |
| Jun 2026 | [GSK plc FDA approval](https://sec-api.dev/companies/gsk/catalysts) | GSK | complicated urinary tract infections | completed, approved | "June 2026, the US FDA approved Utebzi for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritis, caused by certain susceptible pathogens in adult patients who have limited or no alternative oral treatment options." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495426006949/a1493o.htm)) |
| June 17, 2026 | [GSK3036656 topline data readout](https://sec-api.dev/pdufa/gsk3036656) | GSK | Tuberculosis | completed | "NCT05382312 (Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-27 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-06-17." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05382312?tab=results)) |
| June 17, 2026 | [Utebzi (tebipenem pivoxil hydrobromide) FDA approval](https://sec-api.dev/pdufa/tebipenem-pivoxil) | GSK |  | completed, approved | "Utebzi \| tebipenem pivoxil \| 6/17/2026 \| To treat complicated urinary tract infections, including pyelonephritis, caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| June 18, 2026 | [GSK plc PDUFA date](https://sec-api.dev/companies/gsk/catalysts) | GSK |  | scheduled | "The PDUFA date has been set as 18 June 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495426000892/a5979rv2.htm)) |
| June 23, 2026 | [Rsvpref3 oa investigational vaccine topline data readout](https://sec-api.dev/pdufa/rsvpref3-oa-investigational-vaccine) | GSK | Respiratory Syncytial Virus Infections | completed | "NCT06614725 (A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-03 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-06-23." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06614725?tab=results)) |
| June 30, 2026 | [Jemperli (dostarlimab) primary completion](https://sec-api.dev/pdufa/dostarlimab) | GSK | Lung Cancer, Non-Small Cell | completed | "NCT06472076 (A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-30 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06472076)) |
| July 1, 2026 | [Cobolimab topline data readout](https://sec-api.dev/pdufa/cobolimab) | GSK | Lung Cancer, Non-Small Cell | completed | "NCT04655976 (Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-06-05 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-07-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04655976?tab=results)) |
| July 13, 2026 | [Jemperli (dostarlimab) interim data readout](https://sec-api.dev/pdufa/dostarlimab) | GSK | stage II/III mismatch repair deficient/microsatellite instability-high | completed, positive | "GSK plc (LSE/NYSE: GSK) today announced positive interim results from the registrational phase II AZUR-1 trial of Jemperli (dostarlimab) in patients with stage II/III mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) locally advanced rectal cancer." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495426006614/a9768l.htm)) |
| July 14, 2026 | [GSK5784283 primary completion](https://sec-api.dev/pdufa/gsk5784283) | GSK | Asthma | completed | "NCT06748053 (A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-07-14 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06748053)) |
| July 20, 2026 | [Rsvpref3 oa vaccine primary completion](https://sec-api.dev/pdufa/rsvpref3-oa-vaccine) | GSK | Respiratory Syncytial Virus Infections | completed | "NCT07220109 (A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-20 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07220109)) |
| July 22, 2026 | [Zidesamtinib FDA approval](https://sec-api.dev/pdufa/zidesamtinib) | GSK | ROS1-positive NSCLC previously treated | completed, approved | "Following US FDA approval of Jideytro (zidesamtinib) on 22 July 2026, Nuvalent began commercial sales." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495426009181/a6993a.htm)) |
| August 6, 2026 | [Ints-gmma dose c primary completion](https://sec-api.dev/pdufa/ints-gmma) | GSK | Salmonella Infections | completed | "NCT06213506 (A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-06 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06213506)) |
| Aug to Nov 2026 | [Ints-gmma dose c topline data readout](https://sec-api.dev/pdufa/ints-gmma) | GSK | Salmonella Infections | scheduled | "NCT06213506 (A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-06 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06213506)) |
| August 19, 2026 | [Cab la + rpv la primary completion](https://sec-api.dev/pdufa/cab-la-rpv-la) | GSK | HIV Infections | completed | "NCT06694805 (A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-19 (ACTUAL); Lead Sponsor ViiV Healthcare." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06694805)) |
| Aug to Nov 2026 | [Cab la + rpv la topline data readout](https://sec-api.dev/pdufa/cab-la-rpv-la) | GSK | HIV Infections | scheduled | "NCT06694805 (A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-19 (ACTUAL); Lead Sponsor ViiV Healthcare." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06694805)) |
| August 24, 2026 | [Flu mrna (formulation b1) primary completion](https://sec-api.dev/pdufa/flu-mrna-formulation-b1) | GSK | Influenza, Human | completed | "NCT07204964 (A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-24 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07204964)) |
| Aug to Nov 2026 | [Flu mrna (formulation b1) topline data readout](https://sec-api.dev/pdufa/flu-mrna-formulation-b1) | GSK | Influenza, Human | scheduled | "NCT07204964 (A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-24 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07204964)) |
| August 25, 2026 | [Tivicay (dolutegravir sodium) label expansion decision](https://sec-api.dev/pdufa/dolutegravir) | GSK |  | completed, approved | "NDA204790 SUPPL-34 (Efficacy): submission_status AP, submission_status_date 20260825, review_priority PRIORITY; sponsor_name VIIV HLTHCARE; product TIVICAY (DOLUTEGRAVIR SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204790%22)) |
| Sep to Dec 2026 | [Linerixibat topline data readout](https://sec-api.dev/pdufa/linerixibat) | GSK | Cholestasis | scheduled | "NCT04167358 (Linerixibat Long-term Safety, and Tolerability Study): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04167358)) |
| Sep to Dec 2026 | [Nucala (mepolizumab) topline data readout](https://sec-api.dev/pdufa/mepolizumab) | GSK | Eosinophilic Granulomatosis With Polyangiitis | scheduled | "NCT05263934 (Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-29 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05263934)) |
| Sep to Dec 2026 | [Rsvpref3 oa vaccine topline data readout](https://sec-api.dev/pdufa/rsvpref3-oa-vaccine) | GSK | Respiratory Syncytial Virus Infections | scheduled | "NCT06534892 (An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06534892)) |
| Sep to Dec 2026 | [PCV-20 topline data readout](https://sec-api.dev/pdufa/pcv-20) | GSK | Chickenpox | scheduled | "NCT06855160 (A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-09-10 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06855160)) |
| September 4, 2026 | [Dtpa vaccine primary completion](https://sec-api.dev/pdufa/dtpa-vaccine) | GSK | Diphtheria-Tetanus-acellular Pertussis Vaccines | completed | "NCT07596173 (A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Healthy Japanese Adolescents Aged 11 Years to <13 Years): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-04 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07596173)) |
| Sep to Dec 2026 | [Dtpa vaccine topline data readout](https://sec-api.dev/pdufa/dtpa-vaccine) | GSK | Diphtheria-Tetanus-acellular Pertussis Vaccines | scheduled | "NCT07596173 (A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Healthy Japanese Adolescents Aged 11 Years to <13 Years): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-04 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07596173)) |
| September 9, 2026 | [Cab la primary completion](https://sec-api.dev/pdufa/cab-la) | GSK | HIV Infections | completed | "NCT06741397 (A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-09 (ACTUAL); Lead Sponsor ViiV Healthcare." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06741397)) |
| Sep to Dec 2026 | [Cab la topline data readout](https://sec-api.dev/pdufa/cab-la) | GSK | HIV Infections | scheduled | "NCT06741397 (A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-09 (ACTUAL); Lead Sponsor ViiV Healthcare." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06741397)) |
| September 10, 2026 | [Jemperli (dostarlimab) primary completion](https://sec-api.dev/pdufa/dostarlimab) | GSK | Neoplasms, Head and Neck | completed | "NCT06062420 (A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-10 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06062420)) |
| Sep to Dec 2026 | [Jemperli (dostarlimab) topline data readout](https://sec-api.dev/pdufa/dostarlimab) | GSK | Neoplasms, Head and Neck | scheduled | "NCT06062420 (A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-10 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06062420)) |
| September 2026 | [PCV-20 primary completion](https://sec-api.dev/pdufa/pcv-20) | GSK | Chickenpox | delayed | "NCT06855160 (A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-09-10 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06855160)) |
| September 2026 | [Nucala (mepolizumab) primary completion](https://sec-api.dev/pdufa/mepolizumab) | GSK | Eosinophilic Granulomatosis With Polyangiitis | delayed | "NCT05263934 (Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-29 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05263934)) |
| September 2026 | [Linerixibat primary completion](https://sec-api.dev/pdufa/linerixibat) | GSK | Cholestasis | delayed | "NCT04167358 (Linerixibat Long-term Safety, and Tolerability Study): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04167358)) |
| September 2026 | [Rsvpref3 oa vaccine primary completion](https://sec-api.dev/pdufa/rsvpref3-oa-vaccine) | GSK | Respiratory Syncytial Virus Infections | delayed | "NCT06534892 (An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06534892)) |
| October 6, 2026 | [Salbutamol hfa-134a topline data readout](https://sec-api.dev/pdufa/salbutamol-hfa-134a) | GSK | Asthma | completed | "NCT06261957 (A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-02 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-10-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06261957?tab=results)) |
| October 9, 2026 | [AFX3772 topline data readout](https://sec-api.dev/pdufa/afx3772) | GSK | Pneumonia, Bacterial; Pneumococcal Infections; Pneumonia, Pneumococcal | completed | "NCT05412030 (A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-18 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-10-09." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05412030?tab=results)) |
| October 19, 2026 | [Jemperli (dostarlimab) FDA approval](https://sec-api.dev/pdufa/dostarlimab) | GSK | stage II and III microsatellite instability-high | completed, approved | "GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) locally advanced rectal cancer under the accelerated approval pathway." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495426009036/a5712z.htm)) |
| October 19, 2026 | [Jemperli (dostarlimab-gxly) label expansion decision](https://sec-api.dev/pdufa/dostarlimab-gxly) | GSK |  | completed, approved | "BLA761174 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20261019, review_priority PRIORITY; sponsor_name GLAXOSMITHKLINE; product JEMPERLI (DOSTARLIMAB-GXLY)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761174%22)) |
| October 20, 2026 | [HIBSAGO (bepirovirsen) FDA approval](https://sec-api.dev/pdufa/bepirovirsen) | GSK | chronic hepatitis B | completed, approved | "Hibsago \| bepirovirsen \| 10/20/2026 \| To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| October 26, 2026 | [HIBSAGO (bepirovirsen) PDUFA date](https://sec-api.dev/pdufa/bepirovirsen) | GSK |  | completed, approved | "In Q1, the US FDA accepted for priority review a New Drug Application (NDA) for bepirovirsen and set 26 October 2026 as the decision goal date." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495426004051/a2755c.htm)) |
| October 26, 2026 | [Jemperli (dostarlimab) interim data readout](https://sec-api.dev/pdufa/dostarlimab) | GSK | stage II and III microsatellite instability-high | completed, positive | "GSK plc (LSE/NYSE: GSK) today announced positive interim results from the phase II AZUR-1 trial evaluating Jemperli (dostarlimab) monotherapy as a standalone treatment approach in adults with stage II and III microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) locally advanced rectal cancer." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495426009130/a3301a.htm)) |
| October 26, 2026 | [Jemperli (dostarlimab) primary completion](https://sec-api.dev/pdufa/dostarlimab) | GSK | Lung Cancer, Non-Small Cell | completed | "NCT05565378 (A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-26 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05565378)) |
| Oct 2026 to Jan 2027 | [Jemperli (dostarlimab) topline data readout](https://sec-api.dev/pdufa/dostarlimab) | GSK | Lung Cancer, Non-Small Cell | scheduled | "Top-line data expected in Q4 2026 o JADE - pivotal Phase 3 - dostarlimab monotherapy versus placebo in locally advanced unresected head and neck squamous cell carcinoma (PD-L1 hiPghD-L1 CPS≥1) post chemoradiation" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1370053/000119312526088239/anab-ex99_1.htm)) |
| October 26, 2026 | [Altsonflex1-2-3 dose a topline data readout](https://sec-api.dev/pdufa/altsonflex1-2-3) | GSK | Diarrhoea | completed | "NCT06663436 (A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-21 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-10-26." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06663436?tab=results)) |
| October 27, 2026 | [GSK4532990 topline data readout](https://sec-api.dev/pdufa/gsk4532990) | GSK | Non-alcoholic Fatty Liver Disease | completed | "NCT06104319 (Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-23 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-10-27." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06104319?tab=results)) |
| Nov 2026 | [Neladalkib PDUFA date](https://sec-api.dev/pdufa/neladalkib) | GSK |  | scheduled | "Neladalkib is an investigational ALK tyrosine kinase inhibitor (TKI) currently under review with the US FDA for use by patients with TKI pre-treated ALK-positive NSCLC, with PDUFA date anticipated in November 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000119312526384439/d331501d6k.htm)) |
| Nov 2026 to Feb 2027 | [ZEJULA (niraparib) topline data readout](https://sec-api.dev/pdufa/niraparib) | GSK | Neoplasms | scheduled | "NCT03981796 (A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-26 (ESTIMATED); Lead Sponsor Tesaro, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03981796)) |
| Nov 2026 to Feb 2027 | [Jemperli (dostarlimab) topline data readout](https://sec-api.dev/pdufa/dostarlimab) | GSK | Neoplasms, Rectal | scheduled | "NCT05723562 (A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-02 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05723562)) |
| Nov 2026 to Feb 2027 | [Jemperli (dostarlimab) topline data readout](https://sec-api.dev/pdufa/dostarlimab) | GSK | Neoplasms, Colon | scheduled | "NCT06567782 (A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06567782)) |
| Nov 2026 to Feb 2027 | [PCV-20 topline data readout](https://sec-api.dev/pdufa/pcv-20) | GSK | Chickenpox | scheduled | "NCT06693895 (A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06693895)) |
| Nov 2026 to Feb 2027 | [Dtpa topline data readout](https://sec-api.dev/pdufa/dtpa) | GSK | Diphtheria-Tetanus-acellular Pertussis Vaccines | scheduled | "NCT07596199 (A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant Women): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07596199)) |
| November 2026 | [Jemperli (dostarlimab) primary completion](https://sec-api.dev/pdufa/dostarlimab) | GSK | Neoplasms, Rectal | scheduled | "NCT05723562 (A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-02 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05723562)) |
| November 6, 2026 | [Rmenb+omv nz vaccine topline data readout](https://sec-api.dev/pdufa/rmenb-omv-nz-vaccine) | GSK | Meningitis | completed | "NCT06995430 (A Phase 3 Study to Assess the Immune Response and Safety of rMenB+OMV NZ in Primed Healthy Participants (10 to 20 Years Old)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-15 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-11-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06995430?tab=results)) |
| November 2026 | [Jemperli (dostarlimab) primary completion](https://sec-api.dev/pdufa/dostarlimab) | GSK | Neoplasms, Colon | scheduled | "NCT06567782 (A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06567782)) |
| November 2026 | [PCV-20 primary completion](https://sec-api.dev/pdufa/pcv-20) | GSK | Chickenpox | scheduled | "NCT06693895 (A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06693895)) |
| November 2026 | [Dtpa primary completion](https://sec-api.dev/pdufa/dtpa) | GSK | Diphtheria-Tetanus-acellular Pertussis Vaccines | scheduled | "NCT07596199 (A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant Women): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07596199)) |
| November 2026 | [ZEJULA (niraparib) primary completion](https://sec-api.dev/pdufa/niraparib) | GSK | Neoplasms | scheduled | "NCT03981796 (A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-26 (ESTIMATED); Lead Sponsor Tesaro, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03981796)) |
| Dec 2026 to Mar 2027 | [OJJAARA (momelotinib) topline data readout](https://sec-api.dev/pdufa/momelotinib) | GSK | Primary Myelofibrosis | scheduled | "NCT03441113 (Extended Access of Momelotinib in Adults With Myelofibrosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-11 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03441113)) |
| Dec 2026 to Mar 2027 | [ZEJULA (niraparib) topline data readout](https://sec-api.dev/pdufa/niraparib) | GSK | Ovarian Neoplasms; Breast Neoplasms | scheduled | "NCT04641247 (A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-28 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04641247)) |
| Dec 2026 to Mar 2027 | [Jemperli (dostarlimab) topline data readout](https://sec-api.dev/pdufa/dostarlimab) | GSK | Carcinoma | scheduled | "NCT06317311 (A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06317311)) |
| Dec 2026 to Mar 2027 | [PCV-20 topline data readout](https://sec-api.dev/pdufa/pcv-20) | GSK | Chickenpox | scheduled | "NCT06740630 (A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-25 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06740630)) |
| Dec 2026 to Mar 2027 | [PCV-20 topline data readout](https://sec-api.dev/pdufa/pcv-20) | GSK | Chickenpox | scheduled | "NCT06806137 (A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06806137)) |
| Dec 2026 to Mar 2027 | [HFA-152A topline data readout](https://sec-api.dev/pdufa/hfa-152a) | GSK | Asthma | scheduled | "NCT07645248 (A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-28 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07645248)) |
| December 2026 | [OJJAARA (momelotinib) primary completion](https://sec-api.dev/pdufa/momelotinib) | GSK | Primary Myelofibrosis | scheduled | "NCT03441113 (Extended Access of Momelotinib in Adults With Myelofibrosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-11 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03441113)) |
| December 2026 | [Jemperli (dostarlimab) primary completion](https://sec-api.dev/pdufa/dostarlimab) | GSK | Carcinoma | scheduled | "NCT06317311 (A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06317311)) |
| December 2026 | [PCV-20 primary completion](https://sec-api.dev/pdufa/pcv-20) | GSK | Chickenpox | scheduled | "NCT06806137 (A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06806137)) |
| December 2026 | [PCV-20 primary completion](https://sec-api.dev/pdufa/pcv-20) | GSK | Chickenpox | scheduled | "NCT06740630 (A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-25 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06740630)) |
| December 2026 | [ZEJULA (niraparib) primary completion](https://sec-api.dev/pdufa/niraparib) | GSK | Ovarian Neoplasms; Breast Neoplasms | scheduled | "NCT04641247 (A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-28 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04641247)) |
| December 2026 | [HFA-152A primary completion](https://sec-api.dev/pdufa/hfa-152a) | GSK | Asthma | scheduled | "NCT07645248 (A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-28 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07645248)) |
| Jan to Apr 2027 | [Ff/umec/vi topline data readout](https://sec-api.dev/pdufa/ff-umec-vi) | GSK | Asthma | scheduled | "NCT05757102 (A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-26 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05757102)) |
| Jan to Apr 2027 | [Adjuvanted rsvpref3 vaccine topline data readout](https://sec-api.dev/pdufa/adjuvanted-rsvpref3-vaccine) | GSK | Respiratory Syncytial Virus Infections | scheduled | "NCT07092865 (A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01-12 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07092865)) |
| January 2027 | [Adjuvanted rsvpref3 vaccine primary completion](https://sec-api.dev/pdufa/adjuvanted-rsvpref3-vaccine) | GSK | Respiratory Syncytial Virus Infections | scheduled | "NCT07092865 (A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01-12 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07092865)) |
| January 2027 | [Ff/umec/vi primary completion](https://sec-api.dev/pdufa/ff-umec-vi) | GSK | Asthma | scheduled | "NCT05757102 (A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-26 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05757102)) |
| Feb 2027 | [Jemperli (dostarlimab) PDUFA date](https://sec-api.dev/pdufa/dostarlimab) | GSK | previously untreated stage II and III mismatch repair deficient | scheduled | "FDA has assigned a PDUFA action date of February 2027." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495426007798/a7607r.htm)) |
| Mar to Jun 2027 | [Menabcwy vaccine topline data readout](https://sec-api.dev/pdufa/menabcwy-vaccine) | GSK | Meningitis, Meningococcal | scheduled | "NCT05087056 (Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03-10 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05087056)) |
| Mar to Jun 2027 | [OJJAARA (momelotinib) topline data readout](https://sec-api.dev/pdufa/momelotinib) | GSK |  | scheduled | "NCT06517875 (Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-16 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06517875)) |
| Mar to Jun 2027 | [Camlipixant topline data readout](https://sec-api.dev/pdufa/camlipixant) | GSK | Irritable Bowel Syndrome | scheduled | "NCT07519395 (A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-09 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07519395)) |
| March 2027 | [Depemokimab primary completion](https://sec-api.dev/pdufa/depemokimab) | GSK | Asthma | scheduled | "NCT07671001 (A Study of Depemokimab in Participants of 6 to 11 Years of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03-01 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07671001)) |
| Mar to Jun 2027 | [Depemokimab topline data readout](https://sec-api.dev/pdufa/depemokimab) | GSK | Asthma | scheduled | "NCT07671001 (A Study of Depemokimab in Participants of 6 to 11 Years of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03-01 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07671001)) |
| March 2027 | [Camlipixant primary completion](https://sec-api.dev/pdufa/camlipixant) | GSK | Irritable Bowel Syndrome | scheduled | "NCT07519395 (A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-09 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07519395)) |
| March 2027 | [Menabcwy vaccine primary completion](https://sec-api.dev/pdufa/menabcwy-vaccine) | GSK | Meningitis, Meningococcal | scheduled | "NCT05087056 (Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03-10 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05087056)) |
| March 2027 | [OJJAARA (momelotinib) primary completion](https://sec-api.dev/pdufa/momelotinib) | GSK |  | scheduled | "NCT06517875 (Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-16 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06517875)) |
| Apr to Jul 2027 | [HIBSAGO (bepirovirsen) topline data readout](https://sec-api.dev/pdufa/bepirovirsen) | GSK | Hepatitis B | scheduled | "NCT06497504 (Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-22 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06497504)) |
| Apr to Jul 2027 | [Rts,s/as01e vaccine topline data readout](https://sec-api.dev/pdufa/rts-s-as01e-vaccine) | GSK | Malaria | scheduled | "NCT07036159 (A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07036159)) |
| April 2027 | [HIBSAGO (bepirovirsen) primary completion](https://sec-api.dev/pdufa/bepirovirsen) | GSK | Hepatitis B | scheduled | "NCT06497504 (Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-22 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06497504)) |
| April 2027 | [Rts,s/as01e vaccine primary completion](https://sec-api.dev/pdufa/rts-s-as01e-vaccine) | GSK | Malaria | scheduled | "NCT07036159 (A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07036159)) |
| May to Aug 2027 | [HIBSAGO (bepirovirsen) topline data readout](https://sec-api.dev/pdufa/bepirovirsen) | GSK | Chronic Hepatitis B Virus Infection; Hepatitis B | scheduled | "NCT06537414 (A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-31 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06537414)) |
| May to Aug 2027 | [ARAKODA® (tafenoquine) topline data readout](https://sec-api.dev/pdufa/tafenoquine) | GSK | Malaria, Vivax | scheduled | "NCT06666491 (An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-14 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06666491)) |
| May to Aug 2027 | [GSK3862995B topline data readout](https://sec-api.dev/pdufa/gsk3862995b) | GSK | Bronchiectasis | scheduled | "NCT07201051 (A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05-04 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07201051)) |
| May 2027 | [GSK3862995B primary completion](https://sec-api.dev/pdufa/gsk3862995b) | GSK | Bronchiectasis | scheduled | "NCT07201051 (A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05-04 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07201051)) |
| May 2027 | [ARAKODA® (tafenoquine) primary completion](https://sec-api.dev/pdufa/tafenoquine) | GSK | Malaria, Vivax | scheduled | "NCT06666491 (An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-14 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06666491)) |
| May 2027 | [HIBSAGO (bepirovirsen) primary completion](https://sec-api.dev/pdufa/bepirovirsen) | GSK | Chronic Hepatitis B Virus Infection; Hepatitis B | scheduled | "NCT06537414 (A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-31 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06537414)) |
| Jul to Oct 2027 | [OJJAARA (momelotinib) topline data readout](https://sec-api.dev/pdufa/momelotinib) | GSK | Myelodysplastic Syndromes | scheduled | "NCT06847867 (A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-14 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06847867)) |
| Jul to Oct 2027 | [Mrna seasonal flu vaccine topline data readout](https://sec-api.dev/pdufa/mrna-seasonal-flu-vaccine) | GSK | Influenza, Human | scheduled | "NCT07851246 (A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-09 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07851246)) |
| July 2027 | [Mrna seasonal flu vaccine primary completion](https://sec-api.dev/pdufa/mrna-seasonal-flu-vaccine) | GSK | Influenza, Human | scheduled | "NCT07851246 (A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-09 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07851246)) |
| July 2027 | [OJJAARA (momelotinib) primary completion](https://sec-api.dev/pdufa/momelotinib) | GSK | Myelodysplastic Syndromes | scheduled | "NCT06847867 (A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-14 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06847867)) |
| Aug to Nov 2027 | [Hz/su vaccine topline data readout](https://sec-api.dev/pdufa/hz-su-vaccine) | GSK | Herpes Zoster | scheduled | "NCT05371080 (A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05371080)) |
| Aug to Nov 2027 | [Camlipixant topline data readout](https://sec-api.dev/pdufa/camlipixant) | GSK | Refractory Chronic Cough | scheduled | "NCT07650084 (A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08-27 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07650084)) |
| August 2027 | [Hz/su vaccine primary completion](https://sec-api.dev/pdufa/hz-su-vaccine) | GSK | Herpes Zoster | scheduled | "NCT05371080 (A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05371080)) |
| August 2027 | [Camlipixant primary completion](https://sec-api.dev/pdufa/camlipixant) | GSK | Refractory Chronic Cough | scheduled | "NCT07650084 (A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08-27 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07650084)) |
| Oct 2027 to Jan 2028 | [Depemokimab topline data readout](https://sec-api.dev/pdufa/depemokimab) | GSK | Hypereosinophilic Syndrome | scheduled | "NCT05334368 (Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10-29 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05334368)) |
| Oct 2027 to Jan 2028 | [Jemperli (dostarlimab) topline data readout](https://sec-api.dev/pdufa/dostarlimab) | GSK | Neoplasms, Rectal | scheduled | "NCT06640049 (A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10-24 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06640049)) |
| Oct 2027 to Jan 2028 | [VH4524184 topline data readout](https://sec-api.dev/pdufa/vh4524184) | GSK | HIV Infections | scheduled | "NCT07202546 (A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor ViiV Healthcare." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07202546)) |
| Oct 2027 to Jan 2028 | [Gsk3772701 600 mg topline data readout](https://sec-api.dev/pdufa/gsk3772701) | GSK | Malaria, Falciparum | scheduled | "NCT07545681 (A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-08 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07545681)) |
| October 2027 | [Gsk3772701 600 mg primary completion](https://sec-api.dev/pdufa/gsk3772701) | GSK | Malaria, Falciparum | scheduled | "NCT07545681 (A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-08 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07545681)) |
| October 2027 | [Jemperli (dostarlimab) primary completion](https://sec-api.dev/pdufa/dostarlimab) | GSK | Neoplasms, Rectal | scheduled | "NCT06640049 (A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10-24 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06640049)) |
| October 2027 | [VH4524184 primary completion](https://sec-api.dev/pdufa/vh4524184) | GSK | HIV Infections | scheduled | "NCT07202546 (A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor ViiV Healthcare." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07202546)) |
| October 2027 | [Depemokimab primary completion](https://sec-api.dev/pdufa/depemokimab) | GSK | Hypereosinophilic Syndrome | scheduled | "NCT05334368 (Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10-29 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05334368)) |
| Nov 2027 to Feb 2028 | [GSK4532990 topline data readout](https://sec-api.dev/pdufa/gsk4532990) | GSK | Liver Diseases, Alcoholic | scheduled | "NCT06613698 (A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-26 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06613698)) |
| Nov 2027 to Feb 2028 | [Risvutatug rezetecan (ris-rez) topline data readout](https://sec-api.dev/pdufa/risvutatug-rezetecan-ris-rez) | GSK | Neoplasms, Lung | scheduled | "NCT07099898 (A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-05 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07099898)) |
| Nov 2027 to Feb 2028 | [Velzatinib topline data readout](https://sec-api.dev/pdufa/velzatinib) | GSK | Gastrointestinal Neoplasms | scheduled | "NCT07689201 (A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-29 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07689201)) |
| November 2027 | [Risvutatug rezetecan (ris-rez) primary completion](https://sec-api.dev/pdufa/risvutatug-rezetecan-ris-rez) | GSK | Neoplasms, Lung | scheduled | "NCT07099898 (A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-05 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07099898)) |
| November 2027 | [GSK4532990 primary completion](https://sec-api.dev/pdufa/gsk4532990) | GSK | Liver Diseases, Alcoholic | scheduled | "NCT06613698 (A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-26 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06613698)) |
| November 2027 | [Velzatinib primary completion](https://sec-api.dev/pdufa/velzatinib) | GSK | Gastrointestinal Neoplasms | scheduled | "NCT07689201 (A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-29 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07689201)) |
| early 2028 | [DREAMM-10 interim data readout](https://sec-api.dev/pdufa/dreamm-10) | GSK |  | scheduled | "Interim efficacy and safety data for Blenrep as a first line treatment are expected in early 2028 with enrolment expanded to US sites to increase US patient representation in the study population." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495425012307/a1902f-gskoriginaledgar.htm)) |
| Jan to Apr 2028 | [Depemokimab topline data readout](https://sec-api.dev/pdufa/depemokimab) | GSK | Asthma | scheduled | "NCT06979323 (Depemokimab Asthma Imaging and Bronchoscopy Sub-Study): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01-05 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06979323)) |
| January 2028 | [Depemokimab primary completion](https://sec-api.dev/pdufa/depemokimab) | GSK | Asthma | scheduled | "NCT06979323 (Depemokimab Asthma Imaging and Bronchoscopy Sub-Study): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01-05 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06979323)) |
| Feb to May 2028 | [Mocertatug rezetecan topline data readout](https://sec-api.dev/pdufa/mocertatug-rezetecan) | GSK | Neoplasms, Endometrial | scheduled | "NCT07286331 (A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-29 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07286331)) |
| Feb to May 2028 | [Mmrvns topline data readout](https://sec-api.dev/pdufa/mmrvns) | GSK | Measles; Measles-Mumps-Rubella+Chickenpox Vaccine | scheduled | "NCT07406360 (A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07406360)) |
| February 2028 | [Mmrvns primary completion](https://sec-api.dev/pdufa/mmrvns) | GSK | Measles; Measles-Mumps-Rubella+Chickenpox Vaccine | scheduled | "NCT07406360 (A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07406360)) |
| February 2028 | [Mocertatug rezetecan primary completion](https://sec-api.dev/pdufa/mocertatug-rezetecan) | GSK | Neoplasms, Endometrial | scheduled | "NCT07286331 (A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-29 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07286331)) |
| Mar to Jun 2028 | [Efimosfermin alfa topline data readout](https://sec-api.dev/pdufa/efimosfermin-alfa) | GSK | Non-alcoholic Fatty Liver Disease | scheduled | "NCT07221188 (A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-24 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221188)) |
| Mar to Jun 2028 | [Efimosfermin alfa topline data readout](https://sec-api.dev/pdufa/efimosfermin-alfa) | GSK | Non-alcoholic Fatty Liver Disease | scheduled | "NCT07221227 (A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-29 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221227)) |
| March 2028 | [Efimosfermin alfa primary completion](https://sec-api.dev/pdufa/efimosfermin-alfa) | GSK | Non-alcoholic Fatty Liver Disease | scheduled | "NCT07221188 (A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-24 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221188)) |
| March 2028 | [Efimosfermin alfa primary completion](https://sec-api.dev/pdufa/efimosfermin-alfa) | GSK | Non-alcoholic Fatty Liver Disease | scheduled | "NCT07221227 (A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-29 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221227)) |
| Apr to Jul 2028 | [Low dose of ints-tcv topline data readout](https://sec-api.dev/pdufa/low-dose-of-ints-tcv) | GSK | Salmonella Infections | scheduled | "NCT07286370 (A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-04-27 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07286370)) |
| April 2028 | [Low dose of ints-tcv primary completion](https://sec-api.dev/pdufa/low-dose-of-ints-tcv) | GSK | Salmonella Infections | scheduled | "NCT07286370 (A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-04-27 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07286370)) |
| May to Aug 2028 | [Velzatinib - subject to usan approval topline data readout](https://sec-api.dev/pdufa/velzatinib-subject-to-usan-approval) | GSK | Gastrointestinal Neoplasms | scheduled | "NCT07218926 (A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07218926)) |
| May 2028 | [Velzatinib - subject to usan approval primary completion](https://sec-api.dev/pdufa/velzatinib-subject-to-usan-approval) | GSK | Gastrointestinal Neoplasms | scheduled | "NCT07218926 (A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07218926)) |
| Jun to Sep 2028 | [Jemperli (dostarlimab) topline data readout](https://sec-api.dev/pdufa/dostarlimab) | GSK | Neoplasms, Head and Neck | scheduled | "NCT06256588 (A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06256588)) |
| Jun to Sep 2028 | [Mmrvns vaccine topline data readout](https://sec-api.dev/pdufa/mmrvns-vaccine) | GSK | Measles; Mumps; Rubella | scheduled | "NCT07742644 (A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-06-27 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07742644)) |
| Jun to Sep 2028 | [Mrna seasonal flu vaccine topline data readout](https://sec-api.dev/pdufa/mrna-seasonal-flu-vaccine) | GSK | Influenza, Human | scheduled | "NCT07805707 (A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-09 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07805707)) |
| June 2028 | [Mrna seasonal flu vaccine primary completion](https://sec-api.dev/pdufa/mrna-seasonal-flu-vaccine) | GSK | Influenza, Human | scheduled | "NCT07805707 (A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-09 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07805707)) |
| June 2028 | [Mmrvns vaccine primary completion](https://sec-api.dev/pdufa/mmrvns-vaccine) | GSK | Measles; Mumps; Rubella | scheduled | "NCT07742644 (A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-06-27 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07742644)) |
| June 2028 | [Jemperli (dostarlimab) primary completion](https://sec-api.dev/pdufa/dostarlimab) | GSK | Neoplasms, Head and Neck | scheduled | "NCT06256588 (A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06256588)) |
| Jul to Oct 2028 | [Efimosfermin topline data readout](https://sec-api.dev/pdufa/efimosfermin) | GSK | Metabolic Dysfunction-Associated Steatohepatitis; Non-alcoholic Fatty Liver Disease | scheduled | "NCT06920043 (A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-07-03 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06920043)) |
| July 2028 | [Efimosfermin primary completion](https://sec-api.dev/pdufa/efimosfermin) | GSK | Metabolic Dysfunction-Associated Steatohepatitis; Non-alcoholic Fatty Liver Disease | scheduled | "NCT06920043 (A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-07-03 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06920043)) |
| Aug to Nov 2028 | [Efimosfermin alfa topline data readout](https://sec-api.dev/pdufa/efimosfermin-alfa) | GSK | Liver Diseases, Alcoholic | scheduled | "NCT07791043 (A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08-11 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07791043)) |
| August 2028 | [Efimosfermin alfa primary completion](https://sec-api.dev/pdufa/efimosfermin-alfa) | GSK | Liver Diseases, Alcoholic | scheduled | "NCT07791043 (A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08-11 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07791043)) |
| Sep to Dec 2028 | [GSK4527226 topline data readout](https://sec-api.dev/pdufa/gsk4527226) | GSK | Alzheimer's Disease | scheduled | "NCT07105709 (Open-label Extension Study in Participants With Early Alzheimer's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09-15 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07105709)) |
| September 2028 | [GSK4527226 primary completion](https://sec-api.dev/pdufa/gsk4527226) | GSK | Alzheimer's Disease | scheduled | "NCT07105709 (Open-label Extension Study in Participants With Early Alzheimer's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09-15 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07105709)) |
| Oct 2028 to Jan 2029 | [Altsonflex1-2-3 dose a topline data readout](https://sec-api.dev/pdufa/altsonflex1-2-3) | GSK | Diarrhoea | scheduled | "NCT07320716 (Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-10-16 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07320716)) |
| Oct 2028 to Jan 2029 | [Linerixibat topline data readout](https://sec-api.dev/pdufa/linerixibat) | GSK | Pruritus | scheduled | "NCT07860710 (J-LINX: Japan LINerixibat eXtension Study): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-10-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07860710)) |
| October 2028 | [Altsonflex1-2-3 dose a primary completion](https://sec-api.dev/pdufa/altsonflex1-2-3) | GSK | Diarrhoea | scheduled | "NCT07320716 (Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-10-16 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07320716)) |
| October 2028 | [Linerixibat primary completion](https://sec-api.dev/pdufa/linerixibat) | GSK | Pruritus | scheduled | "NCT07860710 (J-LINX: Japan LINerixibat eXtension Study): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-10-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07860710)) |
| Dec 2028 to Mar 2029 | [Depemokimab topline data readout](https://sec-api.dev/pdufa/depemokimab) | GSK | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT06959095 (Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-13 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06959095)) |
| Dec 2028 to Mar 2029 | [Depemokimab topline data readout](https://sec-api.dev/pdufa/depemokimab) | GSK | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT06961214 (Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-13 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06961214)) |
| Dec 2028 to Mar 2029 | [OJJAARA (momelotinib) topline data readout](https://sec-api.dev/pdufa/momelotinib) | GSK | VEXAS Syndrome | scheduled | "NCT07569081 (A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome): Overall Status NOT_YET_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-12-06 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07569081)) |
| December 2028 | [OJJAARA (momelotinib) primary completion](https://sec-api.dev/pdufa/momelotinib) | GSK | VEXAS Syndrome | scheduled | "NCT07569081 (A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome): Overall Status NOT_YET_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-12-06 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07569081)) |
| December 2028 | [Depemokimab primary completion](https://sec-api.dev/pdufa/depemokimab) | GSK | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT06959095 (Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-13 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06959095)) |
| December 2028 | [Depemokimab primary completion](https://sec-api.dev/pdufa/depemokimab) | GSK | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT06961214 (Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-13 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06961214)) |
| Jan to Apr 2029 | [HIBSAGO (bepirovirsen) topline data readout](https://sec-api.dev/pdufa/bepirovirsen) | GSK | Hepatitis B | scheduled | "NCT04954859 (Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-01-24 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04954859)) |
| January 2029 | [HIBSAGO (bepirovirsen) primary completion](https://sec-api.dev/pdufa/bepirovirsen) | GSK | Hepatitis B | scheduled | "NCT04954859 (Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-01-24 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04954859)) |
| Feb to May 2029 | [Belantamab mafodotin topline data readout](https://sec-api.dev/pdufa/belantamab-mafodotin) | GSK | Multiple Myeloma | scheduled | "NCT07614360 (Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-02-28 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07614360)) |
| Feb to May 2029 | [GSK5784283 topline data readout](https://sec-api.dev/pdufa/gsk5784283) | GSK | Asthma | scheduled | "NCT07780643 (A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-02-15 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07780643)) |
| February 2029 | [GSK5784283 primary completion](https://sec-api.dev/pdufa/gsk5784283) | GSK | Asthma | scheduled | "NCT07780643 (A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-02-15 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07780643)) |
| February 2029 | [Belantamab mafodotin primary completion](https://sec-api.dev/pdufa/belantamab-mafodotin) | GSK | Multiple Myeloma | scheduled | "NCT07614360 (Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-02-28 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07614360)) |
| Mar to Jun 2029 | [Jemperli (dostarlimab) topline data readout](https://sec-api.dev/pdufa/dostarlimab) | GSK | Colonic Neoplasms; Neoplasms, Colon | scheduled | "NCT05855200 (Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-19 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05855200)) |
| Mar to Jun 2029 | [Cab la topline data readout](https://sec-api.dev/pdufa/cab-la) | GSK | HIV Infections | scheduled | "NCT06134362 (Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-03-14 (ESTIMATED); Lead Sponsor ViiV Healthcare." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06134362)) |
| Mar to Jun 2029 | [GSK5784283 topline data readout](https://sec-api.dev/pdufa/gsk5784283) | GSK | Nasal Polyps | scheduled | "NCT07782957 (A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-06 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07782957)) |
| Mar to Jun 2029 | [GSK5784283 topline data readout](https://sec-api.dev/pdufa/gsk5784283) | GSK | Nasal Polyps | scheduled | "NCT07782970 (A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-06 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07782970)) |
| Mar to Jun 2029 | [GSK3862995B topline data readout](https://sec-api.dev/pdufa/gsk3862995b) | GSK | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT07915791 (A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-03-16 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07915791)) |
| March 2029 | [GSK5784283 primary completion](https://sec-api.dev/pdufa/gsk5784283) | GSK | Nasal Polyps | scheduled | "NCT07782957 (A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-06 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07782957)) |
| March 2029 | [GSK5784283 primary completion](https://sec-api.dev/pdufa/gsk5784283) | GSK | Nasal Polyps | scheduled | "NCT07782970 (A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-06 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07782970)) |
| March 2029 | [Cab la primary completion](https://sec-api.dev/pdufa/cab-la) | GSK | HIV Infections | scheduled | "NCT06134362 (Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-03-14 (ESTIMATED); Lead Sponsor ViiV Healthcare." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06134362)) |
| March 2029 | [GSK3862995B primary completion](https://sec-api.dev/pdufa/gsk3862995b) | GSK | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT07915791 (A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-03-16 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07915791)) |
| March 2029 | [Jemperli (dostarlimab) primary completion](https://sec-api.dev/pdufa/dostarlimab) | GSK | Colonic Neoplasms; Neoplasms, Colon | scheduled | "NCT05855200 (Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-19 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05855200)) |
| Apr to Jul 2029 | [Depemokimab topline data readout](https://sec-api.dev/pdufa/depemokimab) | GSK | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT07177339 (eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07177339)) |
| April 2029 | [Depemokimab primary completion](https://sec-api.dev/pdufa/depemokimab) | GSK | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT07177339 (eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07177339)) |
| May to Aug 2029 | [Adjuvanted rzv vaccine topline data readout](https://sec-api.dev/pdufa/adjuvanted-rzv-vaccine) | GSK | Cardiovascular Disease | scheduled | "NCT07712380 (A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular Events): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-05-02 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07712380)) |
| May to Aug 2029 | [GSK5784283 topline data readout](https://sec-api.dev/pdufa/gsk5784283) | GSK | Asthma | scheduled | "NCT07782996 (A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-05-04 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07782996)) |
| May 2029 | [Adjuvanted rzv vaccine primary completion](https://sec-api.dev/pdufa/adjuvanted-rzv-vaccine) | GSK | Cardiovascular Disease | scheduled | "NCT07712380 (A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular Events): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-05-02 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07712380)) |
| May 2029 | [GSK5784283 primary completion](https://sec-api.dev/pdufa/gsk5784283) | GSK | Asthma | scheduled | "NCT07782996 (A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-05-04 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07782996)) |
| Jul to Oct 2029 | [Mocertatug rezetecan topline data readout](https://sec-api.dev/pdufa/mocertatug-rezetecan) | GSK | Neoplasms, Endometrial | scheduled | "NCT07684599 (A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07684599)) |
| Jul to Oct 2029 | [GSK5784283 topline data readout](https://sec-api.dev/pdufa/gsk5784283) | GSK | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT07780656 (A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-20 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07780656)) |
| Jul to Oct 2029 | [GSK5784283 topline data readout](https://sec-api.dev/pdufa/gsk5784283) | GSK | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT07780669 (A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-20 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07780669)) |
| July 2029 | [GSK5784283 primary completion](https://sec-api.dev/pdufa/gsk5784283) | GSK | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT07780656 (A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-20 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07780656)) |
| July 2029 | [GSK5784283 primary completion](https://sec-api.dev/pdufa/gsk5784283) | GSK | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT07780669 (A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-20 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07780669)) |
| July 2029 | [Mocertatug rezetecan primary completion](https://sec-api.dev/pdufa/mocertatug-rezetecan) | GSK | Neoplasms, Endometrial | scheduled | "NCT07684599 (A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07684599)) |
| Aug to Nov 2029 | [Benlysta (belimumab) topline data readout](https://sec-api.dev/pdufa/belimumab) | GSK | Systemic Sclerosis Associated Interstitial Lung Disease; Scleroderma, Systemic | scheduled | "NCT05878717 (A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-08-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05878717)) |
| Aug to Nov 2029 | [Benlysta (belimumab) topline data readout](https://sec-api.dev/pdufa/belimumab) | GSK | Lung Diseases, Interstitial | scheduled | "NCT06572384 (A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06572384)) |
| Aug to Nov 2029 | [Cab ula topline data readout](https://sec-api.dev/pdufa/cab-ula) | GSK | HIV | scheduled | "NCT07650916 (A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-13 (ESTIMATED); Lead Sponsor ViiV Healthcare." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07650916)) |
| August 2029 | [Cab ula primary completion](https://sec-api.dev/pdufa/cab-ula) | GSK | HIV | scheduled | "NCT07650916 (A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-13 (ESTIMATED); Lead Sponsor ViiV Healthcare." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07650916)) |
| August 2029 | [Benlysta (belimumab) primary completion](https://sec-api.dev/pdufa/belimumab) | GSK | Systemic Sclerosis Associated Interstitial Lung Disease; Scleroderma, Systemic | scheduled | "NCT05878717 (A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-08-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05878717)) |
| August 2029 | [Benlysta (belimumab) primary completion](https://sec-api.dev/pdufa/belimumab) | GSK | Lung Diseases, Interstitial | scheduled | "NCT06572384 (A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06572384)) |
| Sep to Dec 2029 | [Mocertatug rezetecan topline data readout](https://sec-api.dev/pdufa/mocertatug-rezetecan) | GSK | Ovarian Neoplasms | scheduled | "NCT07694427 (Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-06 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07694427)) |
| September 2029 | [Mocertatug rezetecan primary completion](https://sec-api.dev/pdufa/mocertatug-rezetecan) | GSK | Ovarian Neoplasms | scheduled | "NCT07694427 (Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-06 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07694427)) |
| Dec 2029 to Mar 2030 | [Risvutatug rezetecan (ris-rez) topline data readout](https://sec-api.dev/pdufa/risvutatug-rezetecan-ris-rez) | GSK | Neoplasms, Prostate | scheduled | "NCT07802704 (A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-05 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07802704)) |
| December 2029 | [Risvutatug rezetecan (ris-rez) primary completion](https://sec-api.dev/pdufa/risvutatug-rezetecan-ris-rez) | GSK | Neoplasms, Prostate | scheduled | "NCT07802704 (A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-05 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07802704)) |
| Mar to Jun 2030 | [Jemperli (dostarlimab) topline data readout](https://sec-api.dev/pdufa/dostarlimab) | GSK | Neoplasms, Endometrial | scheduled | "NCT07108270 (A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-03-31 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07108270)) |
| Mar to Jun 2030 | [Jemperli (dostarlimab) topline data readout](https://sec-api.dev/pdufa/dostarlimab) | GSK | Neoplasms, Rectal | scheduled | "NCT07740720 (A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-03-13 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07740720)) |
| March 2030 | [Jemperli (dostarlimab) primary completion](https://sec-api.dev/pdufa/dostarlimab) | GSK | Neoplasms, Rectal | scheduled | "NCT07740720 (A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-03-13 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07740720)) |
| March 2030 | [Jemperli (dostarlimab) primary completion](https://sec-api.dev/pdufa/dostarlimab) | GSK | Neoplasms, Endometrial | scheduled | "NCT07108270 (A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-03-31 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07108270)) |
| May to Aug 2030 | [Mocertatug rezetecan (mo-rez) topline data readout](https://sec-api.dev/pdufa/mocertatug-rezetecan-mo-rez) | GSK | Ovarian Neoplasms | scheduled | "NCT07684612 (A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-05-21 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07684612)) |
| May 2030 | [Mocertatug rezetecan (mo-rez) primary completion](https://sec-api.dev/pdufa/mocertatug-rezetecan-mo-rez) | GSK | Ovarian Neoplasms | scheduled | "NCT07684612 (A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-05-21 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07684612)) |
| Jul to Oct 2030 | [Mocertatug rezetecan topline data readout](https://sec-api.dev/pdufa/mocertatug-rezetecan) | GSK | Ovarian Neoplasms | scheduled | "NCT07286266 (A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-07-22 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07286266)) |
| July 2030 | [Mocertatug rezetecan primary completion](https://sec-api.dev/pdufa/mocertatug-rezetecan) | GSK | Ovarian Neoplasms | scheduled | "NCT07286266 (A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-07-22 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07286266)) |
| Aug to Nov 2030 | [Belantamab mafodotin topline data readout](https://sec-api.dev/pdufa/belantamab-mafodotin) | GSK | Multiple Myeloma | scheduled | "NCT07227311 (A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-08-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07227311)) |
| August 2030 | [Belantamab mafodotin primary completion](https://sec-api.dev/pdufa/belantamab-mafodotin) | GSK | Multiple Myeloma | scheduled | "NCT07227311 (A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-08-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07227311)) |
| Sep to Dec 2030 | [Benlysta (belimumab) topline data readout](https://sec-api.dev/pdufa/belimumab) | GSK | Connective Tissue Diseases | scheduled | "NCT06716606 (A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-27 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06716606)) |
| Sep to Dec 2030 | [Depemokimab topline data readout](https://sec-api.dev/pdufa/depemokimab) | GSK | Asthma | scheduled | "NCT07456033 (A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07456033)) |
| September 2030 | [Depemokimab primary completion](https://sec-api.dev/pdufa/depemokimab) | GSK | Asthma | scheduled | "NCT07456033 (A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07456033)) |
| September 2030 | [Benlysta (belimumab) primary completion](https://sec-api.dev/pdufa/belimumab) | GSK | Connective Tissue Diseases | scheduled | "NCT06716606 (A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-27 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06716606)) |
| Oct 2030 to Jan 2031 | [Efimosfermin alfa topline data readout](https://sec-api.dev/pdufa/efimosfermin-alfa) | GSK | Metabolic Dysfunction-associated Steatohepatitis | scheduled | "NCT07704892 (A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-10-16 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07704892)) |
| October 2030 | [Efimosfermin alfa primary completion](https://sec-api.dev/pdufa/efimosfermin-alfa) | GSK | Metabolic Dysfunction-associated Steatohepatitis | scheduled | "NCT07704892 (A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-10-16 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07704892)) |
| Nov 2030 to Feb 2031 | [Jemperli (dostarlimab) topline data readout](https://sec-api.dev/pdufa/dostarlimab) | GSK | Endometrial Carcinoma; Neoplasms, Endometrial | scheduled | "NCT07860450 (Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-11-05 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07860450)) |
| November 2030 | [Jemperli (dostarlimab) primary completion](https://sec-api.dev/pdufa/dostarlimab) | GSK | Endometrial Carcinoma; Neoplasms, Endometrial | scheduled | "NCT07860450 (Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-11-05 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07860450)) |

## Drugs

- [Triumeq Pd (abacavir sulfate; dolutegravir sodium; lamivudine)](https://sec-api.dev/pdufa/abacavir-dolutegravir-lamivudine): 
- [Epzicom (abacavir sulfate; lamivudine)](https://sec-api.dev/pdufa/abacavir-lamivudine): 
- [Adjuvanted rsvpref3 vaccine](https://sec-api.dev/pdufa/adjuvanted-rsvpref3-vaccine): Respiratory Syncytial Virus Infections
- [Adjuvanted rzv vaccine](https://sec-api.dev/pdufa/adjuvanted-rzv-vaccine): Cardiovascular Disease
- [AFX3772](https://sec-api.dev/pdufa/afx3772): Pneumonia, Bacterial
- [Altsonflex1-2-3 dose a](https://sec-api.dev/pdufa/altsonflex1-2-3): Diarrhoea
- [Belantamab mafodotin](https://sec-api.dev/pdufa/belantamab-mafodotin): Multiple Myeloma
- [Blenrep (belantamab mafodotin-blmf)](https://sec-api.dev/pdufa/belantamab-mafodotin-blmf): 
- [Benlysta (belimumab)](https://sec-api.dev/pdufa/belimumab): Lung Diseases, Interstitial, Systemic Sclerosis Associated Interstitial Lung Disease, Connective Tissue Diseases
- [HIBSAGO (bepirovirsen)](https://sec-api.dev/pdufa/bepirovirsen): chronic hepatitis b, chb infection, Hepatitis B, Chronic Hepatitis B Virus Infection, Hepatitis B, Chronic
- [Cab la](https://sec-api.dev/pdufa/cab-la): HIV Infections
- [Cab la + rpv la](https://sec-api.dev/pdufa/cab-la-rpv-la): HIV Infections
- [Cab ula](https://sec-api.dev/pdufa/cab-ula): HIV
- [Vocabria (cabotegravir sodium)](https://sec-api.dev/pdufa/cabotegravir): HIV Infections
- [Cabenuva Kit (cabotegravir; rilpivirine)](https://sec-api.dev/pdufa/cabotegravir-rilpivirine): 
- [Camlipixant](https://sec-api.dev/pdufa/camlipixant): Irritable Bowel Syndrome, Refractory Chronic Cough
- [Cobolimab](https://sec-api.dev/pdufa/cobolimab): advanced nsclc, Lung Cancer, Non-Small Cell
- [Jesduvroq (daprodustat)](https://sec-api.dev/pdufa/daprodustat): 
- [Depemokimab](https://sec-api.dev/pdufa/depemokimab): Asthma, Hypereosinophilic Syndrome, Pulmonary Disease, Chronic Obstructive
- [Exdensur (depemokimab-ulaa)](https://sec-api.dev/pdufa/depemokimab-ulaa): 
- [Tivicay (dolutegravir sodium)](https://sec-api.dev/pdufa/dolutegravir): HIV
- [Dovato (dolutegravir sodium; lamivudine)](https://sec-api.dev/pdufa/dolutegravir-lamivudine): 
- [Juluca (dolutegravir sodium; rilpivirine hydrochloride)](https://sec-api.dev/pdufa/dolutegravir-rilpivirine): 
- [Jemperli (dostarlimab)](https://sec-api.dev/pdufa/dostarlimab): stage ii and iii microsatellite instability-high, untreated stage ii/iii dmmr/msi-h locally advanced rectal cancer, stage ii/iii mismatch repair deficient/microsatellite instability-high, previously untreated stage ii and iii mismatch repair deficient, Endometrial Carcinoma, Neoplasms, Rectal, Colonic Neoplasms, Carcinoma
- [Jemperli (dostarlimab-gxly)](https://sec-api.dev/pdufa/dostarlimab-gxly): 
- [DREAMM-10](https://sec-api.dev/pdufa/dreamm-10): 
- [Dtg/3tc](https://sec-api.dev/pdufa/dtg-3tc): HIV Infections, HIV
- [Dtpa](https://sec-api.dev/pdufa/dtpa): Diphtheria-Tetanus-acellular Pertussis Vaccines
- [Dtpa vaccine](https://sec-api.dev/pdufa/dtpa-vaccine): Diphtheria-Tetanus-acellular Pertussis Vaccines
- [Efimosfermin](https://sec-api.dev/pdufa/efimosfermin): Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis (NASH)
- [Efimosfermin alfa](https://sec-api.dev/pdufa/efimosfermin-alfa): Metabolic Dysfunction-associated Steatohepatitis, Non-alcoholic Fatty Liver Disease, Liver Diseases, Alcoholic
- [Ff/umec/vi](https://sec-api.dev/pdufa/ff-umec-vi): Asthma
- [Flu mrna (formulation a)](https://sec-api.dev/pdufa/flu-mrna-formulation-a): Influenza, Human
- [Flu mrna (formulation b1)](https://sec-api.dev/pdufa/flu-mrna-formulation-b1): Influenza, Human
- [Arnuity Ellipta (fluticasone furoate)](https://sec-api.dev/pdufa/fluticasone-furoate): 
- [Trelegy Ellipta (fluticasone furoate; umeclidinium bromide; vilanterol trifenatate)](https://sec-api.dev/pdufa/fluticasone-furoate-umeclidinium-vilanterol-trifenatate): 
- [Rukobia (fostemsavir tromethamine)](https://sec-api.dev/pdufa/fostemsavir): 
- [Blujepa (gepotidacin mesylate)](https://sec-api.dev/pdufa/gepotidacin): To treat uncomplicated urinary tract infections
- [GSK1070806](https://sec-api.dev/pdufa/gsk1070806): Dermatitis, Atopic
- [GSK3036656](https://sec-api.dev/pdufa/gsk3036656): Tuberculosis
- [Gsk3511294 (depemokimab)](https://sec-api.dev/pdufa/gsk3511294-depemokimab): Asthma
- [Gsk3772701 600 mg](https://sec-api.dev/pdufa/gsk3772701): Malaria, Falciparum
- [GSK3862995B](https://sec-api.dev/pdufa/gsk3862995b): Bronchiectasis, Pulmonary Disease, Chronic Obstructive
- [GSK3915393](https://sec-api.dev/pdufa/gsk3915393): Idiopathic Pulmonary Fibrosis
- [GSK4527226](https://sec-api.dev/pdufa/gsk4527226): Alzheimer's Disease
- [GSK4532990](https://sec-api.dev/pdufa/gsk4532990): Liver Diseases, Alcoholic, Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
- [GSK5784283](https://sec-api.dev/pdufa/gsk5784283): Pulmonary Disease, Chronic Obstructive, Nasal Polyps, Asthma
- [HFA-152A](https://sec-api.dev/pdufa/hfa-152a): Asthma
- [Hz/su vaccine](https://sec-api.dev/pdufa/hz-su-vaccine): Herpes Zoster
- [Brexafemme (ibrexafungerp)](https://sec-api.dev/pdufa/ibrexafungerp): Candidiasis, Invasive
- [Ints-gmma dose c](https://sec-api.dev/pdufa/ints-gmma): Salmonella Infections
- [Wellcovorin (leucovorin calcium)](https://sec-api.dev/pdufa/leucovorin): 
- [Linerixibat](https://sec-api.dev/pdufa/linerixibat): Cholestasis, Pruritus
- [Low dose of ints-tcv](https://sec-api.dev/pdufa/low-dose-of-ints-tcv): Salmonella Infections
- [Selzentry (maraviroc)](https://sec-api.dev/pdufa/maraviroc): 
- [Menabcwy vaccine](https://sec-api.dev/pdufa/menabcwy-vaccine): Meningitis, Meningococcal
- [Nucala (mepolizumab)](https://sec-api.dev/pdufa/mepolizumab): Asthma, Eosinophilic Granulomatosis With Polyangiitis, Hypereosinophilic Syndrome
- [Mmrvns](https://sec-api.dev/pdufa/mmrvns): Measles
- [Mmrvns vaccine](https://sec-api.dev/pdufa/mmrvns-vaccine): Measles
- [Mocertatug rezetecan](https://sec-api.dev/pdufa/mocertatug-rezetecan): Neoplasms, Endometrial, Ovarian Neoplasms
- [Mocertatug rezetecan (mo-rez)](https://sec-api.dev/pdufa/mocertatug-rezetecan-mo-rez): Ovarian Neoplasms
- [OJJAARA (momelotinib)](https://sec-api.dev/pdufa/momelotinib): To treat intermediate or high-risk myelofibrosis in adults with anemia, Primary Myelofibrosis, VEXAS Syndrome, Myelodysplastic Syndromes
- [Mrna seasonal flu vaccine](https://sec-api.dev/pdufa/mrna-seasonal-flu-vaccine): Influenza, Human
- [Neladalkib](https://sec-api.dev/pdufa/neladalkib): 
- [ZEJULA (niraparib)](https://sec-api.dev/pdufa/niraparib): Ovarian Neoplasms, Neoplasms
- [PCV-20](https://sec-api.dev/pdufa/pcv-20): Chickenpox
- [Rezetecan](https://sec-api.dev/pdufa/rezetecan): 
- [Risvutatug rezetecan (ris-rez)](https://sec-api.dev/pdufa/risvutatug-rezetecan-ris-rez): Neoplasms, Lung, Neoplasms, Prostate
- [Rmenb+omv nz vaccine](https://sec-api.dev/pdufa/rmenb-omv-nz-vaccine): Meningitis
- [Rsvpref3 oa investigational vaccine](https://sec-api.dev/pdufa/rsvpref3-oa-investigational-vaccine): Respiratory Syncytial Virus Infections
- [Rsvpref3 oa vaccine](https://sec-api.dev/pdufa/rsvpref3-oa-vaccine): Respiratory Syncytial Virus Infections
- [Rts,s/as01e vaccine](https://sec-api.dev/pdufa/rts-s-as01e-vaccine): Malaria
- [Salbutamol hfa-134a](https://sec-api.dev/pdufa/salbutamol-hfa-134a): Asthma
- [ARAKODA® (tafenoquine)](https://sec-api.dev/pdufa/tafenoquine): Chronic Babesiosis, Babesiosis, Malaria, Vivax
- [Utebzi (tebipenem pivoxil hydrobromide)](https://sec-api.dev/pdufa/tebipenem-pivoxil): 
- [Velzatinib](https://sec-api.dev/pdufa/velzatinib): Gastrointestinal Neoplasms
- [Velzatinib - subject to usan approval](https://sec-api.dev/pdufa/velzatinib-subject-to-usan-approval): Gastrointestinal Neoplasms
- [VH4524184](https://sec-api.dev/pdufa/vh4524184): HIV Infections
- [Zanamivir](https://sec-api.dev/pdufa/zanamivir): Influenza, Human
- [Zidesamtinib](https://sec-api.dev/pdufa/zidesamtinib): ros1-positive nsclc previously treated

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/gsk/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "GSK catalysts: GSK plc PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/gsk/catalysts

```bibtex
@misc{secapidev_companies_gsk_catalysts_20261116,
  title        = {GSK catalysts: GSK plc PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/gsk/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_gsk_catalysts_20261116","title":"GSK catalysts: GSK plc PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/gsk/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
